NCT02745743View on ClinicalTrials.gov

Phase I Trial of BAY1251152 for Advanced Blood Cancers

PHASE1CompletedINTERVENTIONAL

Enrollment

21

Participants

Timeline

Start Date

June 17, 2016

Primary Completion Date

August 3, 2018

Study Completion Date

August 3, 2018

Conditions

Hematologic Neoplasms

Interventions

DRUG

BAY1251152

Weekly infusion of BAY1251152 in 21-day cycles.

Trial Locations (6)

10032

New York

10461

The Bronx

28040

Madrid

37232

Nashville

01307

Dresden

CF14 4XN

Cardiff

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Bayer

INDUSTRY

NCT02745743 - Phase I Trial of BAY1251152 for Advanced Blood Cancers | Biotech Hunter | Biotech Hunter